18.4 billion painkillers market, sales of the first three enterprises in China accounted for two seats!

Pharmaceutical Network Industry Dynamic" In the global drug market, nervous system drugs have been one of the most important areasIn our country, the nervous system drug market is also the drug enterprises "soldiers must fight" placeIt is understood that in the sub-type pattern, the nervous system drugs mainly have psychotic drugs, painkillers, anesthetics, psychostable drugs, anti-epileptic drugs and other 7 subcategoriesAmong them, the painkiller market, is the nervous system drugs 5 break 10 billion sub-category in the fastest-growing drug marketrecent data show that in 2019 China's public medical institutions terminal painkiller market size has been close to 18.4 billion, it is worth noting that sales of more than 1 billion levels of pharmaceutical companies only three, of which two are domestic enterprisesYangzijiang: 6.78 billion yuan
according to public information, in 2015-2019, the domestic public medical institutions terminal painkiller market "one brother" throne has been firmly occupied by Yangzijiang, its market share has soared from 30.26 percent in 2015 to 36.94 percent in 2019Among them, Dizosin injection is Yangzijiang Pharmaceuticals in the field of painkillers, developed by Wyeth-Ayerst Laboratory, in the United States in 1990In October 2009, The Dizosin injection fluid produced by Yangzijiang Pharmaceutical Group was first marketed, used in the use of opioid analgesic drugs for various pains, and with its high analgesic activity, less respiratory inhibition, constipation, analgesic tolerance and addiction and other adverse reactions advantage, the use of rapid growthSales of Dizosin injections have increased from 602 million yuan in 2013 to 1,863 million yuan in 2018, showing a rapid upward trend in 2015-2017, with growth slowing but not changing in 2018-2019At present, it is understood that Tianjin Pharmaceutical Research Institute, Jiangsu Enhua Pharmaceutical smaller pharmaceutical companies have submitted the listing application for the varietyIn the future, the drug market may be further increasedHengrui Pharmaceuticals: 1.66 billion yuan
currently, the anesthesia business is Hengrui Pharmaceutical's second largest core business It is mainly surgical anaesthetic-related medications, including heptafluerane (inhalation anesthesia), right metormia (anaesthetic sedation), shun aquuke ammonium (myamina), butroinolino (analgesic) four core varieties Among them, the analgesic drug butrine belongs to China's class 2 psychotropic drugs, Hengrui from 2002 in the domestic approval of the butorinol in the injection, is still the domestic market of the sole manufacturer of butorinol In 2018, butofino sales increased nearly fourfold (sample hospital sales figures increased 2.5 times), and in 2018 sales reached 988 million yuan, making it a 1 billion-volume product the sudden rise in the number of drugs, including butrino, was removed in 2015, and hospital data from PDB samples show that the unit price of butrininas has continued to rise since 2015 In fact, in 2018, the 1ml:1mg specification of the Butumorphine injection was raised from the winning bid price of about $13.5 to $36.5, and the 2ml:4mg specification was raised from 38 to 105, which is higher than the average unit price of the PDB sample hospital Sales and gross margin will continue to grow in the future as the adjusted price of the product wins in more provinces.